The Endocannabinoid System and Parkinson Disease

Andrea Giuffrida, Alex Martinez

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Dysregulation of the endocannabinoid system has been implicated in several neurodegenerative disorders including Parkinson disease (PD). Within the motor areas of the brain, cannabinoid and dopamine systems regulate motor function and synaptic plasticity by modulating excitatory and inhibitory neurotransmission. Alterations of this cross talk have been linked to the pathophysiology of PD and the maladaptive plasticity associated with the disabling motor complications caused by long-term use of L-DOPA. This chapter reviews the complex functional interactions between endocannabinoid and dopaminergic/glutamatergic systems in the basal ganglia, the contribution of endocannabinoid transmission dysfunction to PD and L-DOPA-induced dyskinesia, and recent preclinical studies using cannabinoid-based drugs for the pharmacotherapy of these pathologic conditions.

Original languageEnglish (US)
Title of host publicationThe Endocannabinoid System
Subtitle of host publicationGenetics, Biochemistry, Brain Disorders, and Therapy
PublisherElsevier Inc.
Pages63-81
Number of pages19
ISBN (Electronic)9780128096673
ISBN (Print)9780128096666
DOIs
StatePublished - May 16 2017

Fingerprint

Endocannabinoids
Parkinson disease
Parkinson Disease
cannabinoids
Cannabinoids
dyskinesia
Neuronal Plasticity
Dyskinesias
Motor Cortex
neurodegenerative diseases
pathophysiology
Basal Ganglia
dopamine
Synaptic Transmission
Neurodegenerative Diseases
Dopamine
brain
Drug Therapy
drugs
Brain

Keywords

  • Basal ganglia
  • Cannabinoid receptors
  • Endocannabinoids
  • L-DOPA-induced dyskinesia
  • Neurodegeneration

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)

Cite this

Giuffrida, A., & Martinez, A. (2017). The Endocannabinoid System and Parkinson Disease. In The Endocannabinoid System: Genetics, Biochemistry, Brain Disorders, and Therapy (pp. 63-81). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-809666-6.00003-4

The Endocannabinoid System and Parkinson Disease. / Giuffrida, Andrea; Martinez, Alex.

The Endocannabinoid System: Genetics, Biochemistry, Brain Disorders, and Therapy. Elsevier Inc., 2017. p. 63-81.

Research output: Chapter in Book/Report/Conference proceedingChapter

Giuffrida, A & Martinez, A 2017, The Endocannabinoid System and Parkinson Disease. in The Endocannabinoid System: Genetics, Biochemistry, Brain Disorders, and Therapy. Elsevier Inc., pp. 63-81. https://doi.org/10.1016/B978-0-12-809666-6.00003-4
Giuffrida A, Martinez A. The Endocannabinoid System and Parkinson Disease. In The Endocannabinoid System: Genetics, Biochemistry, Brain Disorders, and Therapy. Elsevier Inc. 2017. p. 63-81 https://doi.org/10.1016/B978-0-12-809666-6.00003-4
Giuffrida, Andrea ; Martinez, Alex. / The Endocannabinoid System and Parkinson Disease. The Endocannabinoid System: Genetics, Biochemistry, Brain Disorders, and Therapy. Elsevier Inc., 2017. pp. 63-81
@inbook{9ae06d4d1d35420fba381c8aa7a6097b,
title = "The Endocannabinoid System and Parkinson Disease",
abstract = "Dysregulation of the endocannabinoid system has been implicated in several neurodegenerative disorders including Parkinson disease (PD). Within the motor areas of the brain, cannabinoid and dopamine systems regulate motor function and synaptic plasticity by modulating excitatory and inhibitory neurotransmission. Alterations of this cross talk have been linked to the pathophysiology of PD and the maladaptive plasticity associated with the disabling motor complications caused by long-term use of L-DOPA. This chapter reviews the complex functional interactions between endocannabinoid and dopaminergic/glutamatergic systems in the basal ganglia, the contribution of endocannabinoid transmission dysfunction to PD and L-DOPA-induced dyskinesia, and recent preclinical studies using cannabinoid-based drugs for the pharmacotherapy of these pathologic conditions.",
keywords = "Basal ganglia, Cannabinoid receptors, Endocannabinoids, L-DOPA-induced dyskinesia, Neurodegeneration",
author = "Andrea Giuffrida and Alex Martinez",
year = "2017",
month = "5",
day = "16",
doi = "10.1016/B978-0-12-809666-6.00003-4",
language = "English (US)",
isbn = "9780128096666",
pages = "63--81",
booktitle = "The Endocannabinoid System",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - The Endocannabinoid System and Parkinson Disease

AU - Giuffrida, Andrea

AU - Martinez, Alex

PY - 2017/5/16

Y1 - 2017/5/16

N2 - Dysregulation of the endocannabinoid system has been implicated in several neurodegenerative disorders including Parkinson disease (PD). Within the motor areas of the brain, cannabinoid and dopamine systems regulate motor function and synaptic plasticity by modulating excitatory and inhibitory neurotransmission. Alterations of this cross talk have been linked to the pathophysiology of PD and the maladaptive plasticity associated with the disabling motor complications caused by long-term use of L-DOPA. This chapter reviews the complex functional interactions between endocannabinoid and dopaminergic/glutamatergic systems in the basal ganglia, the contribution of endocannabinoid transmission dysfunction to PD and L-DOPA-induced dyskinesia, and recent preclinical studies using cannabinoid-based drugs for the pharmacotherapy of these pathologic conditions.

AB - Dysregulation of the endocannabinoid system has been implicated in several neurodegenerative disorders including Parkinson disease (PD). Within the motor areas of the brain, cannabinoid and dopamine systems regulate motor function and synaptic plasticity by modulating excitatory and inhibitory neurotransmission. Alterations of this cross talk have been linked to the pathophysiology of PD and the maladaptive plasticity associated with the disabling motor complications caused by long-term use of L-DOPA. This chapter reviews the complex functional interactions between endocannabinoid and dopaminergic/glutamatergic systems in the basal ganglia, the contribution of endocannabinoid transmission dysfunction to PD and L-DOPA-induced dyskinesia, and recent preclinical studies using cannabinoid-based drugs for the pharmacotherapy of these pathologic conditions.

KW - Basal ganglia

KW - Cannabinoid receptors

KW - Endocannabinoids

KW - L-DOPA-induced dyskinesia

KW - Neurodegeneration

UR - http://www.scopus.com/inward/record.url?scp=85041206035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041206035&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-809666-6.00003-4

DO - 10.1016/B978-0-12-809666-6.00003-4

M3 - Chapter

AN - SCOPUS:85041206035

SN - 9780128096666

SP - 63

EP - 81

BT - The Endocannabinoid System

PB - Elsevier Inc.

ER -